Journal of Hematology & Oncology

Scope & Guideline

Unlocking Innovations in Blood Disorders and Cancer Research

Introduction

Immerse yourself in the scholarly insights of Journal of Hematology & Oncology with our comprehensive guidelines detailing its aims and scope. This page is your resource for understanding the journal's thematic priorities. Stay abreast of trending topics currently drawing significant attention and explore declining topics for a full picture of evolving interests. Our selection of highly cited topics and recent high-impact papers is curated within these guidelines to enhance your research impact.
LanguageEnglish
ISSN-
PublisherBMC
Support Open AccessNo
Country-
Type-
Converge-
AbbreviationJ HEMATOL ONCOL / J. Hematol. Oncol.
Frequency1 issue/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
AddressCAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND

Aims and Scopes

The Journal of Hematology & Oncology focuses on advancing the understanding and treatment of hematological malignancies and solid tumors through innovative research and clinical studies. It serves as a platform for disseminating knowledge on the latest therapeutic strategies, including targeted therapies, immunotherapies, and novel treatment modalities.
  1. Hematological Malignancies:
    The journal emphasizes research on various forms of blood cancers, including acute and chronic leukemias, lymphomas, and multiple myeloma, focusing on novel treatment approaches and disease mechanisms.
  2. Immunotherapy Innovations:
    Significant attention is given to immunotherapeutic strategies, including CAR-T cell therapies, checkpoint inhibitors, and bispecific antibodies, aiming to improve patient outcomes in hematological and solid tumors.
  3. Molecular and Genomic Insights:
    Research exploring the genetic and molecular underpinnings of cancers is prominent, with studies investigating mutations, signaling pathways, and the role of non-coding RNAs in disease progression and therapy resistance.
  4. Clinical Trials and Guidelines:
    The journal publishes findings from clinical trials, meta-analyses, and consensus guidelines that inform best practices in the treatment of hematological malignancies and improve patient care.
  5. Translational Research:
    A focus on translational research bridges laboratory findings with clinical applications, aiming to develop new therapeutic strategies and improve existing treatments for cancer patients.
The Journal of Hematology & Oncology has seen a rise in several emerging themes that reflect the current trends in cancer research and treatment. These themes highlight the journal's responsiveness to advancements in the field and the evolving landscape of oncology.
  1. Targeted Therapy and Precision Medicine:
    There is a growing emphasis on targeted therapies and precision medicine approaches that tailor treatments based on individual genetic profiles, enhancing efficacy and minimizing side effects.
  2. Novel Immunotherapeutic Strategies:
    Emerging strategies in immunotherapy, including combination therapies and next-generation CAR-T cell treatments, are trending, reflecting the ongoing innovation in harnessing the immune system to combat cancer.
  3. Role of the Tumor Microenvironment:
    Research exploring the interactions between tumor cells and their microenvironment is gaining traction, with studies examining how these interactions influence treatment responses and tumor progression.
  4. Metabolic Reprogramming in Cancer:
    An increasing number of publications are investigating the metabolic changes in cancer cells and how targeting metabolic pathways can provide new therapeutic opportunities.
  5. Artificial Intelligence and Machine Learning Applications:
    The integration of artificial intelligence and machine learning into cancer research for diagnostics, treatment prediction, and personalized therapy strategies is an emerging and rapidly developing area of focus.

Declining or Waning

While the Journal of Hematology & Oncology continues to thrive in many areas, certain themes have shown a declining trend in recent publications. These themes may be gradually phased out as the field evolves or as new areas of interest emerge.
  1. Traditional Chemotherapy Approaches:
    There is a noticeable decrease in publications focusing solely on traditional chemotherapy regimens as more targeted and personalized treatment options gain prominence in clinical practice.
  2. Basic Laboratory Studies without Clinical Relevance:
    Research that lacks direct clinical applicability or translational potential appears to be receiving less attention, as the journal aims to prioritize studies that can lead to practical therapeutic advancements.
  3. Epidemiological Studies:
    While still relevant, the frequency of epidemiological studies related to cancer incidence and survival rates has waned, possibly due to a shift towards more mechanistic and therapeutic research.

Similar Journals

Experimental Hematology & Oncology

Advancing the Frontiers of Blood and Cancer Research
Publisher: BMCISSN: Frequency: 1 issue/year

Experimental Hematology & Oncology is a premier journal published by BMC, dedicated to advancing knowledge in the fields of hematology, oncology, and cancer research. Since its inception in 2012, this Open Access journal has emerged as a vital resource for researchers and healthcare professionals, fostering the dissemination of high-quality research that enhances our understanding of blood disorders and malignancies. With impressive rankings in Quarters 1 of key categories including Cancer Research, Hematology, and Oncology, it holds significant prestige, evidenced by its Scopus rankings: #42/404 in Medicine (Oncology) and #17/137 in Medicine (Hematology). The journal aims to publish cutting-edge studies, reviews, and perspectives that contribute to the evolution of therapeutic strategies and innovative treatment modalities. Researchers and practitioners alike will find this journal indispensable for staying at the forefront of breakthroughs in hematological and oncological research.

Hematology-American Society of Hematology Education Program

Exploring Innovations in Hematological Science
Publisher: AMER SOC HEMATOLOGYISSN: 1520-4391Frequency: 1 issue/year

Hematology-American Society of Hematology Education Program is a premier peer-reviewed journal dedicated to advancing the field of hematology through comprehensive educational content. Published by the American Society of Hematology, this journal plays a crucial role in disseminating knowledge to researchers, clinicians, and students in hematology and related disciplines. With an impressive Q1 status in the field, it ranks among the top journals at the forefront of hematological research, as evidenced by its 60th percentile ranking in Scopus' Medicine - Hematology category. Although it does not offer open access, the journal provides invaluable insights and educational resources from leading experts, focusing on the latest advancements, treatment protocols, and evolving understanding of blood disorders. Covering a wide range of topics, from basic research to clinical applications, this journal is essential for anyone seeking to deepen their expertise and stay informed on the latest developments in hematology. For further engagement, readers can access insightful articles published since 2001, ensuring a rich repository of knowledge for ongoing research and clinical excellence.

Blood Cancer Journal

Connecting researchers to advance patient outcomes.
Publisher: SPRINGERNATUREISSN: 2044-5385Frequency: 1 issue/year

Blood Cancer Journal, published by SPRINGERNATURE, is a leading open-access journal that has been at the forefront of hematology and oncology research since its inception in 2011. With an impressive impact factor and a commitment to disseminating high-quality research, it holds a prestigious Q1 ranking in both hematology and oncology categories as of 2023. The journal is dedicated to publishing innovative studies, comprehensive reviews, and insightful commentaries that advance our understanding of blood cancers, making it an essential resource for researchers, healthcare professionals, and students in the field. Its open-access model ensures that groundbreaking research is accessible to a global audience, promoting collaborative efforts to enhance treatment methodologies and patient outcomes. With a strong reputation illustrated by its Scopus rankings—8th in hematology and 30th in oncology—Blood Cancer Journal exemplifies excellence and leadership in the ever-evolving landscape of cancer research.

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi

Exploring the frontiers of cancer treatment and research.
Publisher: AKAD DOKTORLAR YAYINEVIISSN: 1306-133XFrequency: 4 issues/year

UHOD-Uluslararasi Hematoloji-Onkoloji Dergisi, published by AKAD DOKTORLAR YAYINEVI, is a pivotal journal in the fields of hematology and oncology, catering to an international audience of researchers, clinicians, and students. Since its inception in 2005, the journal has committed to disseminating high-quality, peer-reviewed research, highlighting advancements and challenges in the diagnosis and treatment of hematological and oncological disorders. Registered under ISSN 1306-133X, it serves as a significant platform for scholarly discourse, despite its recent categorization in the Q4 quartile for both hematology and oncology—indicating opportunities for growth and contribution within the scientific community. While currently not Open Access, the journal's indexed contribution to Scopus ranks it within the 12th and 17th percentiles in the domains of hematology and oncology respectively, reflecting its emerging presence within the academic landscape. As it approaches its convergence point in 2024, UHOD strives to elevate its influence, providing invaluable insights and fostering collaborations in the ongoing fight against blood disorders and cancer.

HEMATOLOGICAL ONCOLOGY

Advancing the Frontiers of Hematological Research
Publisher: WILEYISSN: 0278-0232Frequency: 4 issues/year

HEMATOLOGICAL ONCOLOGY, published by Wiley, is a premier journal in the fields of cancer research, hematology, and oncology, with a rich history of publication dating back to 1983. With an impact factor indicative of its influential standing—ranking in the second quartile in multiple categories including Cancer Research, Hematology, and Oncology—this journal serves as a vital resource for researchers, clinicians, and students alike. HEMATOLOGICAL ONCOLOGY is based in the United Kingdom and focuses on the advancements and challenges in the understanding and treatment of hematological malignancies. While it does not offer open access options, its rigorous peer-review process ensures that all published articles are of the highest quality, contributing to the ongoing dialogue and research in this critical area of medicine. With its commitment to disseminating impactful research, HEMATOLOGICAL ONCOLOGY remains an essential platform for driving innovation and collaboration within the global scientific community.

Indian Journal of Hematology and Blood Transfusion

Transforming Blood Health: Where Research Meets Practice
Publisher: SPRINGER INDIAISSN: 0971-4502Frequency: 4 issues/year

Indian Journal of Hematology and Blood Transfusion, published by SPRINGER INDIA, serves as a leading platform for disseminating original research, reviews, and case studies in the field of hematology. With an ISSN of 0971-4502 and E-ISSN 0974-0449, this journal has been instrumental in advancing knowledge from 2000 to 2024, providing insights into critical issues surrounding blood disorders and transfusion practices. Currently ranked in the Q3 category for Hematology for 2023, it reflects a commitment to high-quality scientific content amidst a competitive landscape where it ranks 97/137 in Scopus for Medicine - Hematology, placing it in the 29th percentile of its peers. The journal primarily addresses a diverse readership, including researchers, healthcare professionals, and students, aiming to foster innovation and collaboration within the field. Although it operates under a subscription model, access options for individual articles and institutional subscriptions ensure that valuable research is disseminated widely to enhance medical practice and education in hematology.

ANNALS OF HEMATOLOGY

Empowering the scientific community with quality contributions.
Publisher: SPRINGERISSN: 0939-5555Frequency: 12 issues/year

ANNALS OF HEMATOLOGY, published by Springer in Germany, stands as a premier platform for advancing knowledge in the field of hematology and medicine at large. With a significant impact factor and recognized rankings—Q2 in Hematology and Q1 in Medicine (miscellaneous) as of 2023—this journal is pivotal for researchers, clinicians, and students who are keen on exploring the latest developments in blood disorders, treatments, and innovative methodologies. Its broad scope encompasses original research, reviews, and discussions that aim to foster interdisciplinary dialogue, ensuring that the latest findings and theories are accessible to the scientific community. Although not an open-access journal, its rigorous peer-review process guarantees high-quality contributions, thereby solidifying its reputation as a vital resource in the hematological field. Founded in 1991, the ANNALS OF HEMATOLOGY continues to evolve, converging invaluable insights from both basic and clinical research until 2024. For those dedicated to improving patient outcomes and advancing hematological science, this journal remains an essential reference.

BLOOD REVIEWS

Elevating knowledge in blood disorders and cancer care.
Publisher: CHURCHILL LIVINGSTONEISSN: 0268-960XFrequency: 6 issues/year

BLOOD REVIEWS is a highly regarded journal published by Churchill Livingstone, specializing in the fields of Hematology and Oncology. With an impressive Q1 ranking in both disciplines and placing in the top 10% of its peer categories according to Scopus metrics, it provides an essential platform for the dissemination of cutting-edge research and reviews pertaining to blood disorders and cancer treatment. Since its inception in 1987 and continuing through 2024, the journal has established itself as a cornerstone for healthcare professionals, researchers, and students who seek to advance their understanding of hematologic and oncologic topics. While not an open-access journal, BLOOD REVIEWS retains a reputation for delivering high-quality, peer-reviewed articles that foster dialogue and innovation within the scientific community. For those in the United States and beyond, the journal serves as a vital resource, housed at the Journal Production Department in Edinburgh, Scotland, ensuring accessibility and a global reach in its critical academic contributions.

Blood Cancer Discovery

Driving Collaborative Efforts for Better Patient Outcomes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2643-3230Frequency: 6 issues/year

Blood Cancer Discovery is a premier academic journal published by the American Association for Cancer Research, dedicated to advancing the understanding of hematologic malignancies through cutting-edge research in the fields of oncology, biochemistry, and molecular biology. With an impressive impact factor and recognition as a Q1 journal across multiple disciplines, including cancer research and hematology, Blood Cancer Discovery serves as an essential platform for scholars and practitioners alike, facilitating impactful discourse and dissemination of pioneering findings. This open-access journal, established within the vibrant academic landscape of the United States, aims to bridge gaps in research and foster collaborations to ultimately enhance patient outcomes. Its Scopus rankings demonstrate its vital role in the critical advancement of cancer research and therapeutic development. By inviting contributions from a diverse range of disciplines, Blood Cancer Discovery is poised to drive innovation and inspire future advancements in understanding blood cancers.

Cancer Discovery

Empowering Research to Transform Cancer Outcomes
Publisher: AMER ASSOC CANCER RESEARCHISSN: 2159-8274Frequency: 12 issues/year

Cancer Discovery, published by the American Association for Cancer Research, stands as a vital resource in the oncological research community, renowned for its commitment to disseminating groundbreaking studies and innovative findings in cancer biology, prevention, diagnostics, and treatment. With a significant impact factor reflecting its esteemed position, this journal facilitates open discussions and collaborations, striving to bridge the gap between experimental and clinical research. The journal, which has been active since 2011, is classified as a Q1 publication in 2023, underscoring its influence and authority in the realm of Oncology. By providing a platform for rigorous peer-reviewed articles, Cancer Discovery aims to advance our understanding of cancer and enhance therapeutic strategies, making it an indispensable tool for researchers, professionals, and students eager to stay at the forefront of cancer research.